Conflicts of interest Dr Ruiz serves as a consultant for Regeneron Inc, Checkpoint Therapeutic, Feldan Pharmaceuticals, and Merck Pharmaceuticals. She serves as a Principal Investigator/Co-Investigator for the following companies: Regeneron (PI/Co-I), Merck (Co-I), and Castle Biosciences (PI/Co-I). She is on the Board of Directors of Skin Cancer Outcomes Consortium (SCOUT). Dr Koyfman is on the advisory board (paid): Merck, BMS, Regeneron, Galera therapeutics; Advisory board (unpaid): Castle Biosciences; Research support: Castle biosciences, Merck, BMS, Regeneron; Honoraria: UpToDate. Dr Vidimos provides research support – Castle; Advisory Board - Inhibitor Therapeutics; Honoraria - Up to Date. Dr Wysong reports institutional research grant from Castle Biosciences. Dr Carr is an investigator for Regeneron, no direct funds. Dr Carucci receives funding for investigator-initiated basic science research from Regeneron and is a PI for a clinical trial sponsored by Regeneron. Dr A Carucci receives grants to institution: Sanofi/Regeneron, Castle-Biosciences; Lectures honoraria: Sanofi, Almirall, Abbvie, Regeneron, Sun Pharma; Payment for expert testimony: Sanofi, Regeneron, Almirall; Support for attending meetings: Pfizer, Almirall, Lilly, Castle-Biosciences; Advisory board: Almirall, Sanofi, Regeneron, Kyowa, Roche, InflaRx; Funding: support by the Gerencia Regional de Salud de Castilla y León (GRS2549/A/22) and by the Instituto de Salud Carlos III (PI21/01207), co-financed by European Union. Dr Mangold has consulted for Phlecs BV, Kyowa, Eli Lilly, Momenta, UCB, and Regeneron in the past, greater than 24 months ago. He has consulted for Incyte, Soligenix, Clarivate, Argenyx, and Bristol Myers Squibb in the past, less than 12 months ago. He consults for PPD, Nuvig, Tourmaline Bio, Janssen, Boehringer Ingelheim, and Biocryst currently. He consults for Regeneron and Pfizer currently with payments to the institution. He has grant support from Kyowa, Miragen, Regeneron, Corbus, Pfizer, Incyte, Eli Lilly, Argenx, Palvella, Abbvie, Priovant, Bristol Myers Squibb, Merck in the last 24 months. Beyond 24 months, grant support has come from Sun Pharma, Elorac, Novartis, and Janssen. He has received royalties from Adelphi Values and Clarivate. His current patents include Methods and Materials for assessing and treating cutaneous squamous cell carcinoma (PCT/US2023/078902), Use of Oral Jaki in Lichen Planus- PCT/US2024/020149; and Topical Ruxolitinib in Lichen Planus- PCT/US2021/053149, 2,023-520,085, & 21805700.8, respectively. Methods and Materials for Treating Lichen Planopilaris (Registration Number: 53,103), Machine-Learning Models for Tumor Grading Using Rank-Aware Contextual Reasoning on Whole Slide Images (63/616,287). Drs Wang, Ran, Granger, Shawan, Hirotsu, Carter, Canueto, Girardi, Srivastava, Nijhawan, Brodland, Zitelli, and Willenbrink have no conflicts of interest to declare.